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Healthcare fi nancing in the United States and elsewhere is likely to be in considerable fl ux for the foreseeable future. Th e aging of the population around much of the world is increasing demand for physician services, while various factors, from improved technology to increased regulation, have caused the infl ation rate for healthcare to exceed that of the general rate of infl ation.
Th e Association of American Medical Colleges' projections point to a substantial shortage of specialist and primary care physicians by 2025. 1 Th ere will be increased requirements for effi ciency and cost-effectiveness, which will aff ect the treatment of allergic rhinitis.
Allergic asthma and allergic rhinitis oft en occur concurrently, although the costs for asthma care are considerably greater. 2 Asthma care provided by specialists has been demonstrated to be cost-eff ective, as well as improving patients' quality of life. 3 What about treatment of allergic rhinitis and, specifi cally, allergen immunotherapy?
Analysis of the cost-eff ectiveness of allergen immunotherapy is diffi cult to perform. Specifi c allergen immunotherapy (SIT) is associated with relatively high up-front costs, but with an expectation of long-term benefi ts. In contrast to the continuous need for medication, SIT commonly produces prolonged benefi t and may be discontinued aft er a 3-to 5-year course. 4 Th e presence of allergic rhinitis has been shown to increase the risk of developing asthma, 5 but a decreased risk of developing asthma has been reported in children with allergic rhinitis treated with SIT. 6 Environmental allergen avoidance may also reduce the risk of sensitization. 7 Th e relationship between the upper and lower airways has been an area of intense interest. 8 In a recent review, Dixon noted that rhinitis and sinusitis are important comorbidities in patients with asthma, concluding, "Retrospective studies suggest that treatment of chronic upper airway disease in established asthma can lead to improved asthma outcomes, though this has not been established in controlled clinical trials. " 9 Th is represents potentially useful additional, but diffi cultto-quantify, cost benefi ts from optimized treatment of allergic rhinitis and sinusitis, including properly done allergy evaluation and specifi c allergy-directed treatment.
It is diffi cult to come up with a single standard of cost for providing a service, but a useful marker in the United States might be considered to be the Medicare allowed amount. In 2010, based on the Medicare allowed amount for a dose of vaccine, 48 weeks of a single dose of vaccine per week (which may contain multiple allergens) is less than $100 per month. Two injections per week would be slightly more than $150 per month, based on that fee schedule. With an everysecond-week regimen, the cost of allergen immunotherapy would drop to $50 per month for one injection and a little more than $80 per month for two injections. In subsequent years, as the interval between injections would increase further, the cost would diminish accordingly.
On www.drugstore.com, generic fl uticasone is just under $60, 10 while newer brand name steroid nasal inhalers are more than $100. A generic topical antihistamine is $95.99, 11 and the brand name product is more than $100. 12 Depending on the patient's response, a doubling of medication needed because of poor control may well be more costly than active immunotherapy, especially as the injection frequency decreases. Once SIT is completed, with a good response, there is no cost for SIT, while medication needs continue.
Th is does not address any additional cost of asthma therapy or the morbidity associated with rhinitis and possible concurrent asthma. Certainly, treatment of rhinitis, without recognition of asthma, may prevent the patient from obtaining optimal results.
As noted in recent guidelines, asthma management requires measures of assessment and monitoring via objective tests (usually spirometry), education, control of environmental factors and comorbid conditions that aff ect asthma, and pharmacologic therapy, as well as specifi c allergen immunotherapy in appropriate patients. 13 Recommendations include periodic measures of lung function, even in patients without complaints such as shortness of breath, as the absence of pulmonary complaints does not exclude the presence of underlying airway obstruction.
Taken together, this supports the evaluation and treatment of allergic respiratory disease as a continuum involving the upper and lower airways, with close collaboration between allergists and otolaryngologists if optimal outcomes are to be achieved. Properly pre- 
